Symbols / PTCT Stock $65.15 +0.14% PTC Therapeutics, Inc.

Healthcare • Biotechnology • United States • NMS
PTCT (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Matthew B. Klein F.A.C.S., M.D., M.S.
Exch · Country NMS · United States
Market Cap 5.40B
Enterprise Value 6.15B
Income 682.64M
Sales 1.73B
FCF (ttm) 211.76M
Book/sh -2.52
Cash/sh 23.50
Employees 991
Insider 10d —
IPO Jun 20, 2013
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 7.59
Forward P/E 26.81
PEG —
P/S 3.12
P/B -25.85
P/C —
EV/EBITDA 6.87
EV/Sales 3.56
Quick Ratio 2.20
Current Ratio 2.35
Debt/Eq —
LT Debt/Eq —
EPS (ttm) 8.58
EPS next Y 2.43
EPS Growth —
Revenue Growth -22.70%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-02-19
ROA 23.26%
ROE —
ROIC —
Gross Margin 70.98%
Oper. Margin -49.57%
Profit Margin 39.44%
Shs Outstand 82.91M
Shs Float 73.00M
Insider Own 7.39%
Instit Own 114.42%
Short Float 14.01%
Short Ratio 8.64
Short Interest 8.55M
52W High 87.50
vs 52W High -25.54%
52W Low 35.95
vs 52W Low 81.22%
Beta 0.55
Impl. Vol. 78.00%
Rel Volume 0.92
Avg Volume 1.15M
Volume 1.05M
Target (mean) $88.07
Tgt Median $86.00
Tgt Low $61.00
Tgt High $124.00
# Analysts 15
Recom Buy
Prev Close $65.06
Price $65.15
Change 0.14%
About

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$88.07
Mean price target
2. Current target
$65.15
Latest analyst target
3. DCF / Fair value
$45.97
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$65.15
Low
$61.00
High
$124.00
Mean
$88.07

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-30 down Jefferies Buy → Hold $76
2026-02-23 main Morgan Stanley Overweight → Overweight $92
2026-02-20 main Wells Fargo Overweight → Overweight $86
2026-02-20 main RBC Capital Sector Perform → Sector Perform $82
2026-02-20 main B of A Securities Buy → Buy $93
2026-01-28 up Barclays Equal-Weight → Overweight $119
2025-12-01 down RBC Capital Outperform → Sector Perform $91
2025-11-06 main Barclays Equal-Weight → Equal-Weight $68
2025-11-05 main Citigroup Neutral → Neutral $75
2025-11-05 main TD Cowen Hold → Hold $63
2025-11-05 main RBC Capital Outperform → Outperform $82
2025-11-05 main Goldman Sachs Sell → Sell $50
2025-11-05 main Wells Fargo Overweight → Overweight $93
2025-10-28 main Jefferies Buy → Buy $77
2025-09-03 reit Cantor Fitzgerald Overweight → Overweight $118
2025-08-20 main Wells Fargo Overweight → Overweight $73
2025-08-20 main Morgan Stanley Overweight → Overweight $71
2025-08-20 main B of A Securities Buy → Buy $76
2025-08-08 main Morgan Stanley Overweight → Overweight $76
2025-08-08 main RBC Capital Outperform → Outperform $63
News
RSS: Latest PTCT news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-21 KLEIN MATTHEW B Chief Executive Officer — 2,850 $70.91 $202,094
2026-04-06 BOULDING MARK ELLIOTT Officer — 2,265 $68.91 $157,293
2026-04-06 BOULDING MARK ELLIOTT Officer — 2,265 $39.42 $89,286
2026-04-02 GOLDEN LEE SCOTT Officer — 829 $67.99 $56,364
2026-04-01 ALMSTEAD NEIL GREGORY Chief Operating Officer — 52,003 $68.89 $3,590,243
2026-03-24 CHUTTER JESSICA CAROLINE Director — 7,333 $0.00 $0
2026-03-12 KLEIN MATTHEW B Chief Executive Officer — 2,662 $64.08 $170,581
2026-03-11 KLEIN MATTHEW B Chief Executive Officer — 12,500 $0.00 $0
2026-03-10 OKEY STEPHANIE S Director — 15,167 $70.00 $1,061,690
2026-03-10 OKEY STEPHANIE S Director — 15,167 $33.63 $510,066
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
1,730.65
+114.51%
806.78
-13.97%
937.82
+34.20%
698.80
Operating Revenue
1,730.65
+114.51%
806.78
-13.97%
937.82
+34.20%
698.80
Cost Of Revenue
47.01
-18.09%
57.40
-12.35%
65.49
+46.57%
44.68
Reconciled Cost Of Revenue
32.94
-22.44%
42.47
-17.58%
51.53
+59.07%
32.40
Gross Profit
1,683.64
+124.67%
749.38
-14.09%
872.34
+33.36%
654.12
Operating Expense
827.13
-7.70%
896.13
-26.65%
1,221.74
+11.67%
1,094.05
Research And Development
455.25
-14.82%
534.48
-19.82%
666.56
+2.31%
651.50
Selling General And Administration
347.14
+15.36%
300.91
-9.51%
332.54
+2.01%
326.00
Total Expenses
874.15
-8.32%
953.53
-25.92%
1,287.22
+13.04%
1,138.73
Operating Income
856.51
+683.66%
-146.75
+58.00%
-349.40
+20.58%
-439.93
Total Operating Income As Reported
866.93
+386.52%
-302.57
+31.16%
-439.50
+1.77%
-447.41
EBITDA
887.66
+836.88%
-120.46
+63.53%
-330.34
+10.18%
-367.78
Normalized EBITDA
877.24
+2380.87%
35.36
+134.44%
-102.68
+71.50%
-360.30
Reconciled Depreciation
38.81
-48.70%
75.66
-68.02%
236.59
+83.64%
128.84
EBIT
848.85
+532.81%
-196.13
+65.41%
-566.93
-14.16%
-496.62
Total Unusual Items
10.43
+106.69%
-155.82
+31.55%
-227.66
-2941.93%
-7.48
Total Unusual Items Excluding Goodwill
10.43
+106.69%
-155.82
+31.55%
-227.66
-2941.93%
-7.48
Special Income Charges
10.43
+106.69%
-155.82
+31.55%
-227.66
-2941.93%
-7.48
Other Special Charges
—
—
137.56
—
Impairment Of Capital Assets
-9.63
-106.01%
160.30
-26.40%
217.80
+552.41%
33.38
Restructuring And Mergern Acquisition
-0.80
+82.12%
-4.47
+96.50%
-127.70
-393.05%
-25.90
Net Income
682.64
+287.90%
-363.30
+42.02%
-626.60
-12.09%
-559.02
Pretax Income
696.62
+291.84%
-363.12
+47.84%
-696.11
-18.49%
-587.49
Net Non Operating Interest Income Expense
-152.23
+8.84%
-166.99
-29.27%
-129.18
-42.16%
-90.87
Interest Expense Non Operating
152.23
-8.84%
166.99
+29.27%
129.18
+42.16%
90.87
Net Interest Income
-152.23
+8.84%
-166.99
-29.27%
-129.18
-42.16%
-90.87
Interest Expense
152.23
-8.84%
166.99
+29.27%
129.18
+42.16%
90.87
Other Income Expense
-7.66
+84.49%
-49.38
+77.30%
-217.53
-283.71%
-56.69
Other Non Operating Income Expenses
-18.09
-116.99%
106.44
+950.78%
10.13
+120.59%
-49.21
Tax Provision
13.97
+7840.34%
0.18
+100.25%
-69.51
-144.14%
-28.47
Tax Rate For Calcs
0.00
-90.43%
0.00
+110.00%
0.00
+106.61%
0.00
Tax Effect Of Unusual Items
0.21
+100.64%
-32.72
-43.74%
-22.77
-6184.98%
-0.36
Net Income Including Noncontrolling Interests
682.64
+287.90%
-363.30
+42.02%
-626.60
-12.09%
-559.02
Net Income From Continuing Operation Net Minority Interest
682.64
+287.90%
-363.30
+42.02%
-626.60
-12.09%
-559.02
Net Income From Continuing And Discontinued Operation
682.64
+287.90%
-363.30
+42.02%
-626.60
-12.09%
-559.02
Net Income Continuous Operations
682.64
+287.90%
-363.30
+42.02%
-626.60
-12.09%
-559.02
Normalized Income
672.43
+379.95%
-240.19
+43.04%
-421.71
+23.59%
-551.90
Net Income Common Stockholders
682.64
+287.90%
-363.30
+42.02%
-626.60
-12.09%
-559.02
Diluted EPS
8.58
+281.40%
-4.73
+43.49%
-8.37
-7.45%
-7.79
Basic EPS
8.58
+281.40%
-4.73
+43.49%
-8.37
-7.45%
-7.79
Basic Average Shares
79.53
+3.50%
76.85
+2.68%
74.84
+4.34%
71.73
Diluted Average Shares
88.31
+14.92%
76.85
+2.68%
74.84
+4.34%
71.73
Diluted NI Availto Com Stockholders
682.64
+287.90%
-363.30
+42.02%
-626.60
-12.09%
-559.02
Amortization
24.74
-59.26%
60.74
-72.72%
222.63
+91.01%
116.55
Amortization Of Intangibles Income Statement
24.74
-59.26%
60.74
-72.72%
222.63
+91.01%
116.55
Depreciation Amortization Depletion Income Statement
24.74
-59.26%
60.74
-72.72%
222.63
+91.01%
116.55
Depreciation And Amortization In Income Statement
24.74
-59.26%
60.74
-72.72%
222.63
+91.01%
116.55
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
2,898.77
+70.01%
1,705.02
-10.06%
1,895.70
+11.14%
1,705.62
Current Assets
2,273.95
+66.52%
1,365.53
+12.05%
1,218.63
+75.65%
693.78
Cash Cash Equivalents And Short Term Investments
1,945.37
+70.69%
1,139.70
+29.99%
876.74
+113.47%
410.70
Cash And Cash Equivalents
984.65
+26.28%
779.71
+31.26%
594.00
+112.27%
279.83
Other Short Term Investments
960.72
+166.88%
359.99
+27.32%
282.74
+116.04%
130.87
Receivables
181.62
+14.55%
158.55
-1.41%
160.82
+3.35%
155.61
Accounts Receivable
181.62
+14.55%
158.55
-1.41%
160.82
+3.35%
155.61
Gross Accounts Receivable
196.82
+22.36%
160.85
-0.72%
162.02
+3.92%
155.91
Allowance For Doubtful Accounts Receivable
-15.20
-560.87%
-2.30
-91.67%
-1.20
-300.00%
-0.30
Inventory
79.65
+243.39%
23.19
-24.15%
30.58
+40.21%
21.81
Raw Materials
2.29
-9.73%
2.54
+166.60%
0.95
-11.69%
1.08
Work In Process
55.69
+355.84%
12.22
-32.10%
17.99
+27.83%
14.07
Finished Goods
21.67
+156.75%
8.44
-27.45%
11.63
+74.79%
6.66
Prepaid Assets
—
—
—
—
Other Current Assets
67.31
+52.67%
44.09
-70.70%
150.49
+42.43%
105.66
Total Non Current Assets
624.82
+84.04%
339.49
-49.86%
677.07
-33.08%
1,011.83
Net PPE
135.42
+15.10%
117.66
-34.27%
178.99
+2.27%
175.02
Gross PPE
182.42
+20.80%
151.01
-34.42%
230.26
+8.41%
212.39
Accumulated Depreciation
-46.99
-40.87%
-33.36
+34.94%
-51.27
-37.21%
-37.37
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
64.40
+7.76%
59.76
-29.01%
84.19
+26.33%
66.64
Construction In Progress
2.80
-7.61%
3.03
-87.36%
24.01
+67.31%
14.35
Other Properties
80.05
+41.22%
56.69
-38.32%
91.90
-10.28%
102.43
Leases
35.16
+11.51%
31.53
+4.52%
30.17
+4.13%
28.97
Goodwill And Other Intangible Assets
471.09
+134.22%
201.13
-56.45%
461.84
-41.41%
788.23
Goodwill
82.34
+0.00%
82.34
+0.00%
82.34
+0.00%
82.34
Other Intangible Assets
388.75
+227.25%
118.79
-68.70%
379.50
-46.24%
705.89
Non Current Prepaid Assets
—
—
—
—
Other Non Current Assets
18.30
-11.60%
20.70
-42.88%
36.25
-25.39%
48.58
Total Liabilities Net Minority Interest
3,104.08
+10.74%
2,803.09
+3.27%
2,714.25
+32.23%
2,052.70
Current Liabilities
968.43
+66.69%
580.98
-3.67%
603.10
+48.46%
406.24
Payables And Accrued Expenses
178.34
-3.12%
184.07
-27.00%
252.16
+30.04%
193.91
Payables
50.58
+53.27%
33.00
+286.19%
8.54
-73.28%
31.98
Accounts Payable
45.49
+163.33%
17.27
+185.76%
6.04
-77.83%
27.27
Other Payable
0.42
-96.23%
11.03
+341.00%
2.50
—
Current Accrued Expenses
127.76
-15.43%
151.07
-37.99%
243.62
+50.45%
161.93
Pensionand Other Post Retirement Benefit Plans Current
73.74
+19.75%
61.58
-1.70%
62.64
-0.04%
62.67
Total Tax Payable
4.68
-0.51%
4.70
0.00
-100.00%
4.71
Income Tax Payable
4.68
-0.51%
4.70
0.00
-100.00%
4.71
Current Debt And Capital Lease Obligation
585.12
+115.76%
271.18
+28.94%
210.32
+148.84%
84.52
Current Debt
569.63
+120.94%
257.82
+32.68%
194.31
+169.32%
72.15
Other Current Borrowings
569.63
+120.94%
257.82
+32.68%
194.31
+169.32%
72.15
Current Capital Lease Obligation
15.48
+15.87%
13.36
-16.49%
16.00
+29.36%
12.37
Current Deferred Liabilities
2.04
-62.94%
5.50
+587.27%
0.80
-40.71%
1.35
Current Deferred Revenue
2.04
-62.94%
5.50
+587.27%
0.80
-40.71%
1.35
Other Current Liabilities
—
—
—
72.15
Total Non Current Liabilities Net Minority Interest
2,135.65
-3.89%
2,222.11
+5.26%
2,111.15
+28.22%
1,646.47
Long Term Debt And Capital Lease Obligation
2,121.95
-3.54%
2,199.89
+8.97%
2,018.81
+46.61%
1,376.99
Long Term Debt
2,025.37
-3.98%
2,109.37
+10.79%
1,904.00
+51.42%
1,257.46
Long Term Capital Lease Obligation
96.58
+6.70%
90.52
-21.16%
114.81
-3.95%
119.53
Tradeand Other Payables Non Current
0.00
-100.00%
0.80
-97.80%
36.30
-77.87%
164.00
Non Current Deferred Liabilities
—
0.00
-100.00%
55.91
-45.64%
102.83
Non Current Deferred Taxes Liabilities
—
0.00
-100.00%
55.91
-45.64%
102.83
Other Non Current Liabilities
13.70
-36.04%
21.43
+15095.74%
0.14
-94.66%
2.64
Stockholders Equity
-205.31
+81.30%
-1,098.07
-34.15%
-818.55
-135.84%
-347.09
Common Stock Equity
-205.31
+81.30%
-1,098.07
-34.15%
-818.55
-135.84%
-347.09
Capital Stock
0.08
+3.90%
0.08
+2.67%
0.07
+4.17%
0.07
Common Stock
0.08
+3.90%
0.08
+2.67%
0.07
+4.17%
0.07
Share Issued
81.47
+4.85%
77.70
+2.64%
75.71
+3.56%
73.10
Ordinary Shares Number
81.47
+4.85%
77.70
+2.64%
75.71
+3.56%
73.10
Additional Paid In Capital
2,748.34
+6.75%
2,574.61
+4.39%
2,466.23
+6.99%
2,305.02
Retained Earnings
-2,964.23
+18.72%
-3,646.87
-11.06%
-3,283.58
-23.58%
-2,656.97
Gains Losses Not Affecting Retained Earnings
10.50
+140.57%
-25.89
-1914.47%
-1.28
-126.79%
4.80
Other Equity Adjustments
10.50
+140.57%
-25.89
-1914.47%
-1.28
-126.79%
4.80
Total Equity Gross Minority Interest
-205.31
+81.30%
-1,098.07
-34.15%
-818.55
-135.84%
-347.09
Total Capitalization
1,820.05
+79.97%
1,011.30
-6.83%
1,085.44
+19.23%
910.37
Working Capital
1,305.52
+66.40%
784.55
+27.46%
615.53
+114.06%
287.55
Invested Capital
2,389.68
+88.30%
1,269.12
-0.83%
1,279.76
+30.25%
982.52
Total Debt
2,707.06
+9.55%
2,471.07
+10.85%
2,229.12
+52.52%
1,461.51
Net Debt
1,610.35
+1.44%
1,587.48
+5.53%
1,504.31
+43.30%
1,049.77
Capital Lease Obligations
112.07
+7.88%
103.88
-20.59%
130.81
-0.83%
131.91
Net Tangible Assets
-676.41
+47.94%
-1,299.21
-1.47%
-1,280.39
-12.78%
-1,135.32
Tangible Book Value
-676.41
+47.94%
-1,299.21
-1.47%
-1,280.39
-12.78%
-1,135.32
Current Provisions
129.20
+120.31%
58.64
-24.01%
77.18
+20.99%
63.79
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
711.20
+760.42%
-107.69
+32.02%
-158.42
+55.58%
-356.65
Cash Flow From Continuing Operating Activities
711.20
+760.42%
-107.69
+32.02%
-158.42
+55.58%
-356.65
Net Income From Continuing Operations
682.64
+287.90%
-363.30
+42.02%
-626.60
-12.09%
-559.02
Depreciation Amortization Depletion
38.81
-48.70%
75.66
-68.02%
236.59
+83.64%
128.84
Depreciation
—
14.90
+7.19%
13.90
+13.01%
12.30
Amortization Cash Flow
—
60.70
-72.73%
222.60
+90.91%
116.60
Depreciation And Amortization
38.81
-48.70%
75.66
-68.02%
236.59
+83.64%
128.84
Amortization Of Intangibles
—
60.70
-72.73%
222.60
+90.91%
116.60
Other Non Cash Items
-20.98
+73.43%
-78.98
+24.54%
-104.67
-56374.19%
0.19
Stock Based Compensation
74.55
-0.09%
74.61
-43.13%
131.21
+18.92%
110.33
Asset Impairment Charge
1.02
-99.38%
163.64
-24.87%
217.80
+552.41%
33.38
Deferred Tax
-0.00
+99.99%
-55.91
-19.14%
-46.93
-36.92%
-34.28
Deferred Income Tax
-0.00
+99.99%
-55.91
-19.14%
-46.93
-36.92%
-34.28
Operating Gains Losses
10.75
+287.65%
-5.73
-114.80%
38.72
+28.07%
30.23
Gain Loss On Investment Securities
7.08
—
-3.60
—
Unrealized Gain Loss On Investment Securities
-9.69
-25.83%
-7.70
-559.67%
1.68
-90.31%
17.29
Net Foreign Currency Exchange Gain Loss
3.38
+132.58%
-10.37
+26.49%
-14.11
-146.81%
30.15
Gain Loss On Sale Of PPE
0.13
-96.98%
4.30
0.00
0.00
Change In Working Capital
-47.88
-146.69%
102.54
+2661.65%
-4.00
+95.31%
-85.33
Change In Receivables
-10.15
-686.09%
1.73
+212.54%
-1.54
+96.82%
-48.47
Changes In Account Receivables
-10.15
-686.09%
1.73
+212.54%
-1.54
+96.82%
-48.47
Change In Inventory
-53.90
-974.37%
6.16
+175.33%
-8.18
-22.72%
-6.67
Change In Prepaid Assets
-34.18
-130.73%
111.22
+379.66%
-39.77
+27.07%
-54.53
Change In Payables And Accrued Expense
71.74
+315.30%
-33.32
-168.92%
48.35
+75.54%
27.54
Change In Other Working Capital
-4.00
-181.31%
4.92
+994.00%
-0.55
-140.71%
1.35
Change In Other Current Liabilities
-17.40
-247.05%
11.83
+612.79%
-2.31
+49.39%
-4.56
Investing Cash Flow
-861.98
-2050.98%
44.18
+125.00%
-176.74
-160.91%
290.18
Cash Flow From Continuing Investing Activities
-861.98
-2050.98%
44.18
+125.00%
-176.74
-160.91%
290.18
Net PPE Purchase And Sale
-8.79
-140.78%
21.55
+175.79%
-28.44
+11.18%
-32.02
Purchase Of PPE
-8.86
-36.27%
-6.50
+77.14%
-28.44
+11.18%
-32.02
Sale Of PPE
0.07
-99.75%
28.06
0.00
0.00
Capital Expenditure
-300.01
-304.06%
-74.25
+38.44%
-120.62
+20.88%
-152.46
Net Investment Purchase And Sale
-562.04
-842.63%
-59.62
-6.25%
-56.12
-112.68%
442.64
Purchase Of Investment
-1,417.16
-112.35%
-667.36
-214.08%
-212.48
-181.25%
-75.55
Sale Of Investment
855.12
+40.71%
607.74
+288.66%
156.37
-69.82%
518.19
Net Intangibles Purchase And Sale
-291.15
-329.76%
-67.75
+26.51%
-92.18
+23.47%
-120.44
Purchase Of Intangibles
-291.15
-329.76%
-67.75
+26.51%
-92.18
+23.47%
-120.44
Net Other Investing Changes
—
150.00
—
—
Financing Cash Flow
331.09
+29.40%
255.87
-60.42%
646.40
+284.87%
167.95
Cash Flow From Continuing Financing Activities
331.09
+29.40%
255.87
-60.42%
646.40
+284.87%
167.95
Net Issuance Payments Of Debt
-1.61
-8.12%
-1.49
+99.51%
-301.38
-302.64%
148.72
Issuance Of Debt
—
0.00
0.00
-100.00%
300.00
Repayment Of Debt
-1.61
-8.12%
-1.49
+99.51%
-301.38
-99.22%
-151.28
Long Term Debt Issuance
—
0.00
0.00
-100.00%
300.00
Long Term Debt Payments
-1.61
-8.12%
-1.49
+99.51%
-301.38
-99.22%
-151.28
Net Long Term Debt Issuance
-1.61
-8.12%
-1.49
+99.51%
-301.38
-302.64%
148.72
Net Common Stock Issuance
—
0.00
0.00
-100.00%
50.00
Proceeds From Stock Option Exercised
99.05
+193.35%
33.76
+12.57%
29.99
+42.27%
21.08
Net Other Financing Charges
233.66
+4.50%
223.59
-75.64%
917.78
+1869.94%
-51.85
Changes In Cash
180.31
-6.27%
192.36
-38.20%
311.25
+206.71%
101.48
Effect Of Exchange Rate Changes
22.71
+409.93%
-7.33
-335.32%
3.11
+212.34%
-2.77
Beginning Cash Position
795.32
+30.32%
610.28
+106.23%
295.93
+50.05%
197.22
End Cash Position
998.33
+25.53%
795.32
+30.32%
610.28
+106.23%
295.93
Free Cash Flow
411.18
+326.00%
-181.94
+34.80%
-279.04
+45.19%
-509.11
Interest Paid Supplemental Data
5.70
-2.08%
5.82
-83.88%
36.13
+95.69%
18.46
Income Tax Paid Supplemental Data
36.85
+109.99%
17.55
+23.98%
14.15
+187.59%
4.92
Amortization Of Securities
-18.02
-43.84%
-12.53
-469.50%
-2.20
-228.43%
1.71
Common Stock Issuance
—
0.00
0.00
-100.00%
50.00
Issuance Of Capital Stock
—
0.00
0.00
-100.00%
50.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category